Open Beta
TREN
MetriLume
TREN

US marketsMBRX

SEC-sourced researchBeta

MBRX

Moleculin Biotech, Inc.

Company comparison ↗

Data passport

CIK
0001659617
Exchange
Nasdaq
Business activity
— · SIC 2834
Financial inputs
6/6
Filing date
Oct 5, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 0.0000 USD; December 2025: 0.0000 USD0 USD0 USD0December 2024December 2025
MBRX · Exact amounts and source periods · USD
Period endRevenueFiling date
December 20240.0000Mar 18, 2026
December 20250.0000Mar 18, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 20250.0000-33,560,000.0000-22,735,000.000022,126,000.00007,120,000.0000Mar 18, 2026
December 20240.0000-26,048,000.0000-23,862,000.000016,925,000.00005,717,000.0000Mar 18, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenues$0December 2025Mar 18, 202610-K
Previous period revenueRevenues$0December 2024Mar 18, 202610-K
Net incomeNetIncomeLoss-$33.56MDecember 2025Mar 18, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$22.74MDecember 2025Mar 18, 202610-K
Total assetsAssets$22.13MDecember 2025Mar 18, 202610-K
Total liabilitiesLiabilities$7.12MDecember 2025Mar 18, 202610-K

New filings

Explore methodology ↗